The IDegAsp co-formulation provides both FPG and PPG control, and allows flexibility in the timing of dosing (e.g., for people travelling across time zones, shift workers or those who rely on healthcare providers to administer their insulin during home visits) in a simple regimen with fewer injections than basal-bolus regimens and a lower rate of hypoglycaemia than premix, basal-plus or basal-bolus regimens [41,42,43]. This evidence concerns the gene INS and Hypoglycemia.